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Abstract 
 Tumors can be depicted as wounds that never heal, and are infiltrated by a large array of 
inflammatory and immune cells. Tumor-associated chronic inflammation is a hallmark of cancer that 
fosters progression to a metastatic stage, as has been extensively reviewed lately. Indeed, 
inflammatory cells persisting in the tumor establish a cross-talk with tumor cells that may result in a 
phenotype switch into tumor-supporting cells. This has been particularly well described for 
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 Epithelial-to-mesenchymal transition (EMT), the embryonic program that loosens cell-cell 
adherence complexes and endows cells with enhanced migratory and invasive properties, can be co-
opted by cancer cells during metastatic progression. Cancer cells that have undergone EMT are more 
aggressive, displaying increased invasiveness, stem-like features and resistance to apoptosis. 
 
 EMT programs can also stimulate the production of pro-inflammatory factors by cancer cells. 
Conversely, inflammation is a potent inducer of EMT in tumors. Therefore, the two phenomena may 
sustain each other, in an alliance for metastasis. This is the focus of this review, where the 
interconnections between EMT programs and cellular and molecular actors of inflammation are 
described. We also recapitulate data linking the EMT/inflammation axis to metastasis. 
 
1. Introduction  
While acute, transitory inflammation is an essential actor of tissue damage control and 
repair, tumor-associated inflammation – which occurs in virtually all tumors – is of a chronic, 
unresolved type (Pesic and Greten, 2016) that fosters tumor progression. During tumorigenesis, 
cancer cells, innate immune cells (such as dendritic cells or tumor-associated macrophages, TAMs) 
and activated resident cells (such as cancer-associated fibroblasts, CAFs or endothelial cells) produce 
a variety of cytokines and chemokines in response to the danger signals originating from the tumor. 
These soluble factors drive the recruitment of massive amounts of additional bone marrow-derived 
innate immune cells, which fuel the so-called cytokine storm (Crusz and Balkwill, 2015). This 
prolonged reaction favors tumor cell survival and proliferation, immunosuppression (by the 
inhibition of effector immune cells and the accumulation of myeloid suppressive cells) and 
angiogenesis (Becht et al., 2016). Promisingly, multiple anti-inflammatory agents are under 
development and/or under clinical testing currently in chemoprevention trials (Crusz and Balkwill, 
2015). 
 
The understanding that tumor cells are genetically and phenotypically very heterogeneous 
has further stimulated studies aiming at deciphering how different tumor cell phenotypes may relate 
to tumor-associated inflammation. During the metastatic progression of epithelial tumors, tumor 
cells indeed undergo phenotypic changes, essentially driven by environmental stimuli, allowing the 
tumor cells to adapt to the different microenvironment encountered (adjacent stroma, blood, or 
colonized organs). Epithelial-to-mesenchymal transition (EMT) appears today as a major actor 
modulating these phenotypic conversions. Though two recent studies (Fischer et al., 2015; Zheng et 
al., 2015) have revived the debate about the universal requirement of EMT in the metastasis 
process, the current dogma is that EMT processes might be involved in the initial steps of the 
metastatic cascade, including tumor invasion, intravasation and micrometastases formation. This has 
been supported by multiple in vitro and in vivo functional data, as well as by correlative data in 
human samples (Diepenbruck and Christofori, 2016). The acquisition of EMT-like changes in tumor 
cells has been extensively studied and implies increased invasive properties, resistance to DNA 
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features. EMT transcriptomic signatures are found highly associated with groups of patients with 
poorer outcome in multiple cancer entities including breast cancer (Jang et al., 2015), colorectal 
cancer (Roepman et al., 2014), head and neck cancer (Pan et al., 2016) or malignant pleural 
mesothelioma (de Reynies et al., 2014). EMT-associated signaling pathways have lately been 
considered as therapeutic targets, as recently shown in a murine pancreatic cancer model 
(Subramani et al., 2016). In this study, metastasis was successfully hampered by the use of 
Nimbolide, a drug which, among other effects, reduced EMT via the induction of excessive 
production of reactive oxygen species. EMT signaling pathways have also been targeted in breast 
cancer in vitro models (Yu et al., 2016), or even in clinical settings (Marcucci et al., 2016). 
 
Increasing literature data have thus emphasized a link between cancer-associated EMT and 
chronic inflammation. Indeed, inflammatory mediators (soluble factors, oxidative stress or hypoxia 
for example) can foster the acquisition of EMT-like features in cancer cells (Lopez-Novoa and Nieto, 
2009) (Table 1). Conversely, these cancer cells can produce a higher amount of pro-inflammatory 
mediators, such as cytokines, chemokines and matrix metalloproteinases (MMPs), which fuel the 
cancer-related, smoldering inflammation. In this review, we highlight most recent data including in 
vitro and in vivo models describing the connections between EMT signaling pathways and (i) innate 
immune cells and (ii) soluble mediators of inflammation (inflammatory cytokines and chemokines). 
Finally, we present some in vivo functional studies and human correlative data, associating EMT and 
inflammation with tumor progression and metastasis. 
 
2. EMT and the cellular actors of inflammation  
 Inflammatory cells in a tumor can be of multiple origins. These cells comprise activated 
resident cells, such as endothelial cells or cancer-associated fibroblasts (CAFs) or resident 
macrophages (TAMs) or dendritic cells. In addition, the tumor milieu recruits bone-marrow-derived 
cells, mostly neutrophils, macrophages and immature, immunosuppressive myeloid cells called 
MDSCs (myeloid-derived suppressive cells). In this section, we review the interconnection between 
EMT and recruitment and/or polarization or such cells. 
 
2.1. EMT and myeloid cells 
a. TAMs 
Among immune cells infiltrating solid tumors, TAMs are most likely the most abundant cell 
type as they make up to 50% of the tumor mass (Solinas et al., 2009). Even though macrophages 
should be able to kill tumor cells, provided they get the appropriate activation signals, the 
chronically inflamed/immunosuppressive microenvironment most often polarizes TAMs into tumor-
supporting cells (schematically categorized in “M2-like macrophages”) that promote extracellular 
matrix remodeling, angiogenesis, immunosuppression, and foster the acquisition of invasive 
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The global numbers of TAMs have been correlated to EMT-like features in several cancer 
entities. This has been reported in a cohort of 178 gastric cancer patients, where CD68-positive cell 
density is associated with the expression of EMT features in cancer cells (E-cadherin loss and 
vimentin de novo expression). This was also demonstrated in an independent study using another 
marker of TAMs, CD163. In that study, high intratumoral CD163 expression was found to be 
correlated to E-cadherin loss (Yan et al., 2016). Global density of macrophages also relates to EMT 
features in non-small cell lung cancer carcinoma (NSCLC) (Bonde et al., 2012) or head and neck 
cancer (Hu et al., 2016). 
 
 Spatial association of cancer cells with EMT features and macrophages has also been 
described in a murine model of terato-carcinoma. Tumor areas rich in macrophages indeed contain 
more tumor cells displaying E-cadherin loss, β-catenin accumulation and fibronectin expression 
compared to areas poor in macrophages (Bonde et al., 2012). Similarly, such a spatial clustering has 
been revealed in a human cohort of hepatocellular carcinoma (Fu et al., 2015). 
 
Functionally, TAMs have been described as potent EMT inducers in numerous independent 
studies. TAMs accordingly produce multiple growth factors (HGF, EGF, TGF, PDGF etc.) and 
inflammatory cytokines (IL-1β, IL-6 and TNFα) that each can induce EMT in cancer cells (Figure 1). In 
vitro data from pancreatic cancer cell lines have demonstrated that co-culture of cancer cells with 
M2-polarized macrophages is able to foster the acquisition of EMT-like properties in cancer cells, 
including spindle-shaped morphology, decreased E-cadherin and increased vimentin expression, 
invasive properties and enhanced production of MMPs (Liu et al., 2013). Mechanistically, the 
TLR4/IL-10 axis has been involved in this process and inhibition of either effectively represses EMT 
induction. M2-TAM-induced EMT has also been reported in co-cultures of mouse cancer cells in a 
murine model of terato-carcinoma. Interestingly, depletion of macrophages using clodronate 
liposomes in these mice decreases the expression of mesenchymal features in primary tumors 
(Bonde et al., 2012). 
 
In hepatocellular carcinoma, macrophages induce EMT in cancer cells in co-culture experiments, in 
an IL-8-dependent fashion (Fu et al., 2015) or in a TGFβ-dependent fashion (Deng et al., 2016; Fan et 
al., 2014) . In other tumor types such as NSCLC, macrophages are known to induce EMT via EGF (Ravi 
et al., 2016).  
On the other hand, the EMT-program in cancer cells might facilitate polarization of TAM into 
M2-like, tumor supporting cells. Indeed, conditioned media from mesenchymal-like breast cancer 
cell lines activate macrophages into a TAM-like phenotype, including high expression of CD206 (a 
scavenger receptor also known as Macrophage mannose receptor or MMR) and high secretion of 
CCL17, CCL18, CCL22 and IL-10 (Su et al., 2014). This effect is mediated by the production of GM-CSF, 
which has accordingly been associated to EMT in breast cancer (Su et al., 2014; Suarez-Carmona et 
al., 2015). GM-CSF-activated macrophages in turn induce EMT in breast cancer cells, in a CCL18-
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b. Other myeloid cells  
In a transgenic murine model of melanoma (the RETAAD mice, expressing the activated RET 
oncogene), MDSCs preferentially infiltrated the primary tumor in comparison to metastases. Mostly 
recruited following a CXCL5 gradient (whose human orthologues, CXCL1 and IL-8, are expressed by 
cancer cells), these immunosuppressive cells could in turn promote EMT-like changes in cancer cells, 
via multiple pathways comprising TGF, EGF and HGF (Figure 1). Most interestingly, depletion of 
MDSCs using an anti-Ly6G antibody led to a decrease in EMT marker expression (namely vimentin 
and S100A4/FSP1) (Toh et al., 2011).  
 
A couple of years ago, we observed that conditioned media from cancer cells induced for 
EMT could recruit CD11b+ GR1+ myeloid cells in vivo in a murine model. Similarly, in a cohort of 40 
triple-negative breast cancer samples, tumors infiltrated by high numbers of CD33-positive myeloid 
cells were more susceptible to display EMT features (as measured by vimentin expression in above 
10% of the tumor cells) (Suarez-Carmona et al., 2015). Accordingly, in a cohort of 97 high-grade 
breast cancer patients, a high extracellular matrix-related gene expression profile (“ECM3”, 
characterized by high SPARC and collagen expression) correlates with a high expression of EMT 
transcription factor (EMT-TF) Twist1 and high numbers of infiltrating CD33-positive myeloid cells 
(Sangaletti et al., 2016). Whether these myeloid cells are mature (neutrophils) or immature (MDSCs) 
cells is still unclear, because of a marker overlap both in mice (CD11b-Ly6G stain neutrophils and 
their progenitors) and in human (CD33 stains the whole myeloid lineage) (Ugel et al., 2015). A way to 
discriminate between immature myeloid cells and neutrophils in human immunohistochemistry 
studies could be to use a stain for myeloperoxidase (MPO), used in routine to detect finally activated 
neutrophils, or other markers of differentiated neutrophils, such as CD66b. We mention hereafter 
two studies in which specifically mature neutrophils were involved in the acquisition of EMT traits by 
cancer cells. In the first study, the density of infiltrating neutrophils was studied in pancreatic cancer 
biopsies using a staining for elastase, presumably expressed by differentiated cells (Grosse-Steffen et 
al., 2012). As a result, high density of neutrophils was related to the nuclear accumulation of beta-
catenin and ZEB1 in tumors. These finding were not reproducible in hepatocellular carcinoma. In 
addition, co-culture of neutrophils induced EMT in cancer cells in vitro. The mechanism involved was 
a disruption of E-cadherin-mediated cell-cell adhesion by neutrophil-derived elastase (Grosse-
Steffen et al., 2012). In another study, neutrophils were detected using CD66b in lung 
adenocarcinoma specimens. CD66b is expressed by activated neutrophils and eosinophils. The 
density of intratumoral CD66b was inversely correlated to E-cadherin expression (Hu et al., 2015). 
Consistently with the study mentioned above (Grosse-Steffen et al., 2012), co-culture between 
neutrophils and lung cancer cell lines resulted in EMT trait acquisition and increased migration, in a 
process requiring TGFβ this time (Hu et al., 2015). 
 
The important functional role of myeloid cells, particularly immunosuppressive immature 
myeloid cells (MDSCs), in inducing EMT has been illustrated in an elegant study using high-grade 
breast cancers (Sangaletti et al., 2016). Ectopic expression of SPARC in high-grade breast cancer cells 
leads to the acquisition of EMT features in vivo but not in vitro, highlighting the role of the 
microenvironment in this process. Tumors formed by cancer cells ectopically expressing SPARC, in 
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myeloid cells (CD11b+GR1+) with strong immunosuppressive functions (as measured by their ability 
to inhibit anti-CD3 and CD28-induced T cell proliferation in vitro). Inhibition of these suppressive 
functions using zoledronic acid effectively reverses EMT in tumors in vivo. Moreover, zoledronic 
acid-treated, SPARC-expressing tumor cells have a higher mitotic index and are accordingly more 
sensitive to Doxil, compared to their untreated counterparts (Sangaletti et al., 2016).Supportively, an 
independent, veterinary group has reported induction of EMT-like changes in vitro by coculturing 
canine tumor cells with MDSCs. This occurs in an IL-28/IL-28R-dependent way (Mucha et al., 2014) 
(Figure 1). 
 
2.2. EMT and adaptive immune cells  
Beyond MDSCs, there is a strong connection between EMT and chronic inflammation-
associated immunosuppression in cancer progression (Chen et al., 2014; Chen et al., 2015a). This 
immunosuppression involves regulatory dendritic cells (DCregs), regulatory T cells (Tregs) and 
effector T cell exhaustion by the expression of immune checkpoints. 
 
In mice bearing NSCLC, the immune checkpoint PD-L1 is detected on tumor cells expressing 
the EMT transcription factor ZEB1. PD-L1 binds its receptor PD-1 at the surface of T cells and this is 
associated to T cell dysfunction, decreased tumor-infiltrating lymphocyte (TIL) density and 
metastasis outburst (Chen et al., 2014). This link between EMT and immunosuppression seems to be 
conserved in humans since the authors could identify, using two independent gene expression data 
sets, that EMT gene signature in lung adenocarcinoma is related to the upregulated expression of 
multiple immune checkpoints (PD-1/PD-L1, CTLA-A, TIM-3 and others), to high Foxp3-positive Treg 
cell density, to immunosuppressive cytokine production (TGFβ, IL-10 and IL-6) and, finally, to a 
strong inflammatory reaction (indeed, CD4+ Treg cells produce high amounts of pro-inflammatory 
cytokines such as IL-10, TNF-α or IL-6) (Chen et al., 2014). This has been recently confirmed in human 
cancer. Breast cancer cells undergoing EMT indeed express PD-L1 in a miR-200- and ZEB1-dependent 
fashion (Noman et al., 2017). 
 
In mouse melanoma xenografts, Snail1 transfectants (which promote Treg expansion in 
vitro) recruit both Tregs and DCregs in vivo. The latter would depend on melanoma cell-derived CCL2 
(Kudo-Saito et al., 2013). Local immunosuppression and resistance to DC immunotherapy is 
abrogated by intratumoral injection of an anti-Snail1 siRNA, or by anti-TSP1 (thrombospondin 1) 
treatment (Kudo-Saito et al., 2009), underlining the central role of EMT programs in cancer 
progression in this model. 
Indoleamine 2,3 dioxygenase (IDO) is mainly a tumor cell-derived, inflammation-induced, 
immunosuppressive factor (Muller et al., 2008; Uyttenhove et al., 2003) that promotes tumor 
progression. Ricciardi and collaborators have recently reported a decreased viability and/or 
proliferation of natural killer (NK) cells and of T cells after co-culture with cancer cell lines in which 
EMT had been induced (Ricciardi et al., 2015). This effect was triggered by an IFN-γ-mediated IDO 
overexpression in cancer cells and was blocked by co-culture in the presence of the IDO inhibitor L-
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Finally, in hepatocellular carcinoma cell lines, hypoxia or HIF-1α expression triggers EMT-like 
changes including E-cadherin loss and morphological modifications. Simultaneously, HIF-1α binds to 
a HRE (hypoxia response element) on the CCL20 promoter and induces CCL20 expression by cancer 
cells (Ye et al., 2016). Hypoxic tumor cell-derived CCL20 induced IDO expression in macrophages, 
which leads to decreased T cell proliferation and increased Foxp3+ Treg cell proportions after co-
culture (Ye et al., 2016). 
 
3. EMT and soluble factors of inflammation  
Further supporting the relationship between the cellular actors of inflammation and EMT 
detailed above, extensive literature has also linked EMT and soluble mediators of inflammation. As 
we review hereafter, several of these soluble mediators, mostly cytokines and chemokines, have 
been shown to trigger EMT in various cancer cell types. Conversely, EMT-derived tumor cells have 
also been shown to over-produce many pro-inflammatory mediators, thereby establishing a 
regulatory loop that may contribute to maintain both the EMT phenotype and the pro-inflammatory 
context.  
 
It is important to consider that tumor-associated EMTs rarely involve a complete lineage 
switching but rather generate intermediate states (hybrid phenotypes) with varying degrees of 
aggressiveness that distribute along the epithelial to the mesenchymal differentiation spectrum. 
Correspondingly, there is a multiplicity of EMT molecular repertoires involved in the generation of 
these hybrid phenotypes. As detailed here under and summarized in Table 1, the extent of EMT 
induction by specific pro-inflammatory mediators and the molecular EMT actors affected accordingly 
vary greatly. If specific responses may be triggered by specific pro-inflammatory mediators, several 
EMT-related changes are commonly induced by several mediators. These common modifications 
include – but are not limited to – a diminution of E-cadherin, an induction of vimentin and other 
mesenchymal markers (FSP1, N-cadherin, MMP9), an expression of EMT-TFs, the acquisition of 
enhanced migratory and invasive properties. 
 
Below, we review in vitro-based studies that identified relationships and regulatory loops 
linking EMT and specific well-known pro-inflammatory mediators. Animal and clinical studies that 
functionally involve these EMT/cytokine regulatory loops in the metastatic progression are discussed 
in a separate chapter (section 4). 
3.1. TGFβ 
TGFβ is a key actor of cancer-related inflammation, but its effects on immune cells are very 
broad. TGFβ promotes chemotaxis of eosinophils, macrophages and mast cells. It skews macrophage 
and neutrophil polarization into tumor-promoting, immunosuppressive cells. TGFβ also negatively 
impacts the anti-tumor immune response by multiple mechanisms (inhibition of antigen-presenting 
functions of DCs, suppression of cytotoxic functions of CD8+ T cells, promotion of development of 










Molecular Oncology (2017) © 2017 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
Dijke, 2016). Finally, in the tumor microenvironment, production of TGFβ originates from multiple 
cells like tumor cells, fibroblasts, macrophages, leukocytes, endothelial cells etc. (Papageorgis and 
Stylianopoulos, 2015). The role of TGFβ in cancer metastasis in general, and in cancer EMT in 
particular, has been massively documented (for a few examples, see Table 1). It has been reviewed, 
several times, elsewhere (Moustakas and Heldin, 2016; Papageorgis and Stylianopoulos, 2015; 
Pickup et al., 2013; Pickup et al., 2017; Zhang et al., 2016a). 
3.2. TNFα 
Tumor necrosis factor alpha (TNFα) was historically so named because it induces 
hemorrhagic necrosis of tumors. Its dual role has since been studied and it is now widely accepted 
that chronic exposure to TNFα rather promotes tumor cell proliferation, angiogenesis and 
dissemination. TNFα can control the expression of multiple other cytokines and TNF-neutralization 
agents are used to treat cancer (Crusz and Balkwill, 2015). 
 
The induction of EMT by TNFα, particularly in synergy with TGFβ or other inflammatory 
factors, has been described (Bates and Mercurio, 2003) (Figure 2 and Table 1). For instance, a mix of 
TGFβ, IFN-α and TNFα can be used to induce EMT-like changes in human cancer cell lines in vitro 
(Ricciardi et al., 2015). Treatment of cancer cells with the supernatant from a mixed lymphocyte 
reaction (MLR) experiment induces a similar phenotype (Ricciardi et al., 2015). In colorectal cancer 
cell lines, TNFα and TGFβ induce EMT-like changes either in a NLRP3/Snail1 axis-dependent way 
(NLRP3 stands for “NOD-like receptor family, pyrin domain containing 3”) (Song et al., 2016), or via 
an increase in expression of Claudin-1. In this case, Claudin-1 is delocalized away from the 
membrane, and activates the Src and ERK1/2 MAP kinases pathways (Bhat et al., 2016). TNFα-
induced EMT has been reported in cell lines from multiple other cancer entities: hepatocellular 
carcinoma (Zhu et al., 2016), breast cancer (Cohen et al., 2015), lung cancer (Song et al., 2016) or 
thyroid cancer (here in combination with IFNγ) (Lv et al., 2015) among others. Interestingly, TNFα 
treatment-induced EMT signaling pathways in renal cell carcinoma cell lines requires expression of 
CXCR2, CXCR3 and their ligands (Sun et al., 2016), highlighting synergy with chemokines. 
3.3. IL-1  
Interleukin-1β (IL-1β) is a major cytokine involved in cancer-associated chronic inflammation 
(Crusz and Balkwill, 2015). A few reports have illustrated a causative link between the IL-1β/IL-1R 
axis and induction of EMT-like changes in (pre-) cancerous cells in vitro (Table 1). Li and collaborators 
initially showed that IL-1β treatment promotes EMT in primary colorectal cancer cells via ZEB1 
overexpression (Li et al., 2012b). IL-1β also induces EMT in oral squamous cell carcinoma (OSCC) cell 
lines and in primary dysplastic oral keratinocytes. Interestingly, in these cells, IL-1β-induced EMT 
leads to enhanced secretion of the pro-inflammatory cytokines IL-6, IL-8 and GROα (Lee et al., 2015), 
thereby initiating a potential autocrine EMT-maintenance loop. Finally, in the MCF10A cells, ectopic 
expression of EMT-TF Snail1 leads to hyper responsiveness to IL-1β, characterized by high activation 
of NF-kB and MAPK pathways and production of IL-6 and IL-8 (Lim et al., 2013) (Figure 2). This is in 
line with the textbook signaling pathway of IL-1β, which, upon binding to its IL-1R (a dimeric cytokine 
receptor), leads to activation of the NF-κB pathway and initiates a pro-inflammatory program in a 
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3.4. IL-8  
Although IL-8 can be secreted by a variety of stromal cells, EMT pathways induce IL-8 
expression and secretion in tumor cells as shown in human breast cancer cell lines (Brysse et al., 
2012; Li et al., 2012a; Lim et al., 2013; Suarez-Carmona et al., 2015), in immortalized oral 
keratinocytes (Lyons et al., 2008), in lung cancer cell lines (Fernando et al., 2011) and in colorectal 
cancer cell lines (Bates et al., 2004) or in colorectal cancer cells freshly isolated from human tumors 
(Hwang et al., 2011). In this last model, Snail1 has been shown to directly promote IL-8 transcription 
upon binding to E3/E4 E-boxes. Finally, there is a correlation between Snail1 and IL-8 protein 
expression in a cohort of 52 human colorectal cancer specimens (Hwang et al., 2011). Other reports 
have highlighted the functional role of EMT-TFs Twist (Li et al., 2012a), Brachyury (Fernando et al., 
2011) and the Snail family (Suarez-Carmona et al., 2015) in the regulation of IL-8 expression in 
cancer cell lines. Most recently, Lesage and collaborators have demonstrated that the molecule ZO-
1, located at the membrane in epithelial cells but transported into the nuclear/cytoplasmic 
compartment upon EMT-associated junction disruption, activates the secretion of IL-8 via the NF-kB 
pathway in breast and lung cancer cell lines (Lesage et al., 2017). 
 
 Conversely, IL-8 can induce EMT (Table 1). IL-8 can bind to two G-protein-coupled receptors, 
CXCR1/2, and initiate several signaling pathways, such as Ras/Raf/MAPK, PI3K, or JAK/STAT (Figure 
2). IL-8-mediated EMT has been demonstrated in ovarian cancer cell lines (Yin et al., 2015), breast (Ji 
et al., 2016) and lung cancer cells. In these, Erlotinib-induced autocrine IL-8 production induces EMT 
via the p38 MAPK kinase pathway (Figure 2). IL-8 neutralization effectively restores an epithelial 
phenotype (Fernando et al., 2016). IL-8 additionally triggers EMT changes in thyroid cancer cells via 
the AKT/Slug pathway (Visciano et al., 2015) and in hepatocellular carcinoma, via JAK2/STAT3 
activation and Snail1 expression (Fu et al., 2015). Finally, Zhang and collaborators have recently 
shown that, in nasopharyngeal carcinoma cells, IL-8 stabilizes the DN methyl-transferase DNMT1 via 
AKT, thereby inducing methylation of E-cadherin promoter, leading to E-cadherin repression and 
EMT program activation (Zhang et al., 2016e). Cooperative induction of EMT in colorectal cancer 
cells has been shown upon IL-8 and CCL20 treatment, in conditions in which each individual 
treatment failed to induce EMT. This combined effect involves the activation of the PI3K, Akt and 
ERK1/2 pathways (Cheng et al., 2014). 
 
Altogether, the data linking IL-8 and EMT have established the principle of a mutual loop in 
which IL-8 and EMT programs sustain each other in the cancer microenvironment (Long et al., 2016). 
 
3.5. IL-6  
The role of IL-6 in cancer-related inflammation has been reviewed elsewhere (Pesic and 
Greten, 2016). IL-6, produced both by tumor cells (especially after Ras or p53 mutations) and by 
reactive stromal cells (Crusz and Balkwill, 2015), promotes both local and systemic inflammation. 
Elevated circulating levels of IL-6 are an indicator of a poor outcome in several cancer entities (Crusz 
and Balkwill, 2015). IL-6 binds to a dimeric cytokine receptor composed of IL-6Rα and IL-6Rβ/gp130. 
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tumors, tumor cells can produce a soluble form of IL-6Rα which binds to IL-6, enabling the so-formed 
dimer to interact with gp130 at the surface of cancer cells and initiate pro-survival signaling (Naugler 
and Karin, 2008). 
 
The reciprocal causative link between EMT pathways and IL-6 has been supported by a 
number of independent studies (Table 1). Historically, the negative effect of IL-6 on E-cadherin 
expression in breast cancer cell lines was already demonstrated almost twenty years ago (Asgeirsson 
et al., 1998). Later, Sullivan and collaborators demonstrated the induction of EMT phenotypes in 
estrogen receptor alpha-positive breast cancer cells (Sullivan et al., 2009). In this work, the ectopic 
expression of IL-6 in MCF7 cells activated the JAK2/STAT3 pathway and Twist, leading to the 
acquisition of mesenchymal markers and properties (Figure 2). More recently, a role for IL-6 in 
inducing and maintaining EMT was shown in other breast cancer cell lines. IL-6, induced by TrkC 
(tropomyosin receptor kinase C) triggers EMT and Twist1-mediated IL-6 overexpression, initiating a 
vicious loop securing the EMT phenotype (Kim et al., 2016). IL-6 also induces EMT in vitro in 
immortalized epithelial oral cells, in a JAK2/STAT3/Snail1-dependent way (Yadav et al., 2011), in lung 
adenocarcinoma cells (in a STAT3-Snail1-dependent fashion) (Zhao et al., 2014) and in NSCLC cells 
(Lee et al., 2016; Shintani et al., 2016). In this latter case, the effects of IL-6 are more pronounced in 
the CD133+, stem-like, subpopulation (Lee et al., 2016). IL-6 also induces EMT in ovarian cancer cells, 
similarly via the JAK2/STAT3 signaling pathway (Colomiere et al., 2009) (Figure 2); in head and neck 
squamous cell carcinoma cells (Wu et al., 2016a), in gastric cancer cells (Chen et al., 2017) and in 
uterine cervix cancer cells (in a STAT3-Slug-dependent way) (Miao et al., 2014). Finally, an additional 
pathway has been linked to IL-6-mediated EMT in colorectal cancer cells (Rokavec et al., 2014). 
Phosphorylated STAT3 can directly repress miR-34 (a miRNA involved in the maintenance of the 
epithelial phenotype, mostly by inhibiting the EMT transcription factor Snail1) by binding on its first 
intron. MiR-34 is a p53-regulated target that represses IL-6Rα (Rokavec et al., 2014).  
 
On the contrary, the induction of EMT in cancer cell lines can foster expression of IL-6 at 
quite high levels in breast cancer cell lines via Twist (Sullivan et al., 2009) or Snail1 (Suarez-Carmona 
et al., 2015) and in oral keratinocytes via Snail1 (Lyons et al., 2008). The pathways involved in Snail1-
mediated IL-6 (and IL-8) mRNA expression have been detailed in the immortalized breast cells 
MCF10A (Lim et al., 2013) and comprise ERK, STAT2/3 and AKT activation. 
3.6. Th17-related cytokines  
Tumor infiltration by the pro-inflammatory Th17 T cells is associated to increased Th17-
associated cytokines IL-23, IL-17, IL-1β and IL-6. In esophageal cancer, IL-23 expression in the 
primary tumor relates to the presence of nodal and distance metastases (Deyu et al., 2015). In vitro, 
treatment of esophageal cancer cell lines with recombinant IL-23 induces EMT-like changes 
characterized by loss of E-cadherin and de novo vimentin expression (Deyu et al., 2015). The 
signaling pathways in these cells comprise activation of the Wnt/βcatenin pathway, subsequent GSK-
3β stabilization, which finally triggers Slug and Snail1 expression (Figure 2). Regarding IL-17, 
treatment with recombinant IL-17 was shown to induce EMT-like changes in three human cell lines 
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also results in EMT-like changes including E-cadherin loss, de novo vimentin acquisition and 
increased migratory and invasive properties (Jiang et al., 2017) and associates with STAT3 
phosphorylation. 
3.7. CCL2  
CCL2 (or monocyte chemotactic protein 1, MCP1) is produced by several cell types and 
recruits most immune cells (except from neutrophils and eosinophil) by binding to its receptor CCR2. 
CCL2 expression in cancer correlates with TAM density (Deshmane et al., 2009). 
 
CCL2 expression leads to EMT in several cancer cell types (Table 1). In lung cancer cell lines, 
CCL2 and IL-6 synergistically induce EMT in a Twist/STAT3-dependent fashion (Chen et al., 2015b) 
(Figure 2). CCL2 neutralization also inhibits EMT in prostate cancer cells (Izumi et al., 2013). Finally, in 
bladder cancer, mast cells induce EMT in cancer cells via stimulation of the ERβ/CCL2/CCR2 axis (Rao 
et al., 2016).  
 
On the contrary, in mouse melanoma cells, ectopic Snail1 expression leads to EMT and 
subsequently to CCL2 production (Kudo-Saito et al., 2013).  
3.8. CCL5  
CCL5 is a pro-inflammatory chemokine involved in inflammatory cell recruitment, cancer-
related angiogenesis and tumor metastasis formation (Aldinucci and Colombatti, 2014). Its 
receptors, CCR1, CCR3, and mostly CCR5, are expressed at the surface of myeloid cells, T cells and 
tumor cells. Recently, CCL5 has emerged as an EMT-inducer (Table 1). CCL5 was indeed identified as 
a T cell-derived, pro-EMT factor in human colorectal cancer-liver metastasis tissue (Halama et al., 
2016). In ovarian cancer models, CCL5 has also been shown to be produced by CD133-positive stem-
like cancer cells. By binding to CCR1/3/5 on CD133-negative, non-stem-like cells, CCL5 activates NF-
κB and thereby promotes EMT and metastasis (Long et al., 2015). Finally, CCL5 derived from the 
adipose microenvironment fosters invasive properties of triple-negative breast cancer cells in vitro 
(D'Esposito et al., 2016).  
3.9. CCL18  
CCL18 is a macrophage-derived, T cell-attracting chemokine. CCL18 is only expressed in 
human, not in mice; recent data indicate that it binds to CCR8 (Islam et al., 2013). 
 
A few reports have linked CCL18 to EMT in cancer (Table 1). In pancreatic cancer cells for example, 
CCL18 is expressed both by tumor cells and M2-polarized macrophages. In vitro, recombinant CCL18 
induces migration, and invasion, as well as EMT-TF Snail1 expression in pancreatic cancer cell lines 
(Meng et al., 2015). In breast cancer cell lines, CCL18 derived from TAMs activates NF-κB and 
thereby induces EMT-like changes including spindle-shape morphology, E-cadherin-to-vimentin 
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Finally in the ovarian cancer cell line Skov3, CCL18 ectopic expression endows tumor cells with 
enhanced migratory and invasive properties in vitro (although the authors do not investigate the 
expression of any marker or transcription factor linked to EMT) (Wang et al., 2016). 
3.10. CCL20  
In human colorectal cancer, CCL20 receptor CCR6 is overexpressed in tumors compared to 
normal tissue, and expression intensity increases with tumor stage, suggesting a functional role in 
aggressiveness. Supportively, the authors also show that colorectal cancer cells undergo EMT 
changes when exposed to CCL20 in vitro. This is inhibited by neutralizing CCR6 (Kapur et al., 2016) 
(Table 1). Additionally, co-occurrence of CCL20 expression and EMT have been reported in 
hepatocellular cancer (Ye et al., 2016), as described in section 2.2. 
3.11. CCL21  
In a panel of pancreatic cancer cell lines, CCR7 is found overexpressed specifically in stem-
like CD133-positive cells, (Table 1). Activation of this receptor by CCL21 leads to the acquisition of 
EMT markers (E-to-N-cadherin switch, MMP9 expression) and increased invasive properties. This 
involves Erk/NF-κB signaling (Zhang et al., 2016c). 
 
Expression of the CCL21 receptor CCR7 is also increased in breast cancer cells upon TGF-β-induced 
EMT, which facilitates breast cancer cell migration towards CCL21-positive, draining lymphatic 
vessels in mice, in a DC-like fashion (Pang et al., 2016). 
3.12. Reactive oxygen species (ROS) 
 During an inflammatory reaction, ROS are mostly produced by activated macrophages or 
neutrophils. They activate adaptive immune cells and contribute to apoptosis induction. In addition, 
ROS are major regulators of the production of pro-inflammatory cytokines and chemokines (such as 
CXCL12), (Costa et al., 2014). Whether these major actors of inflammation impact the EMT program 
in cancer cells has been investigated for the past few years. 
 
Nevertheless, the effect of ROS on the induction – or inhibition – of EMT programs in cancer cells is 
unclear, since opposite effects of ROS on EMT induction in cancer cells have been described. The 
production of ROS has been shown to inhibit EMT in two prostate cancer cell lines (Das et al., 2014). 
Similarly, in basal-like breast carcinoma cells, Snail1-induced epigenetic silencing of FBP1 (fructose-1, 
6-biphosphatase) on one hand promotes glycolysis and the production of NAPDH (via the pentose 
phosphate pathway), and on the other hand decreases respiration, leading to the decreased 
production of ROS, which finally endows tumor cells with cancer stem cell- and EMT-like features 
(Dong et al., 2013). Conversely, the inhibition of mitochondrial ROS in cervical cancer cells reverses 
the acquisition of EMT-like properties (Shagieva et al., 2016). In colorectal cancer cell lines, 
oxaliplatin-induced EMT depends on ROS production (Jiao et al., 2016). Accordingly, the drug 
Nimbolide, which has been successfully used to reduce metastasis in a mouse pancreatic cancer 











Molecular Oncology (2017) © 2017 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
4. EMT, inflammation and the metastatic progression 
 There has been a plethora of studies consistently linking chronic inflammation to cancer 
progression and metastatic outgrowth (Crusz and Balkwill, 2015; Grivennikov and Karin, 2010; 
Muller et al., 2008; Naugler and Karin, 2008; Pesic and Greten, 2016). Similarly, many publications 
have illustrated the pro-metastatic effects of EMT program activation in cancer cells (Bates and 
Mercurio, 2005; Fassina et al., 2012; Spaderna et al., 2006; Yu et al., 2013). Research data indicating 
that an alliance, or mutual loop, between EMT-like cancer cells and established chronic inflammation 
promote metastasis in a cooperative fashion, are rather scarce. We here focus on these few studies 
and mention the role of the EMT/inflammation axis in tumorigenesis, invasion, liberation of 
circulating tumor cells and metastasis outburst. 
 
 The EMT/inflammation axis is already involved in the very first steps of tumor formation. For 
instance, ectopic expression of Snail1 in colorectal cancer cells induces properties of colonospheres 
including stem cell properties and IL-8 expression, leading to increased tumorigenicity in nude mice 
(Hwang et al., 2011). Similarly, subcutaneous injection of gastric quiescent cancer stem cells to nude 
mice after 24h of treatment with IL-17, which induces EMT-like changes in vitro, results in the 
formation of larger xenografts in nude mice (Jiang et al., 2017). Accordingly, in PTENnull MMP7null 
mice and PTENnull IL-17RCnull mice, prostate tumors are smaller and a lower proportion of mice 
develop invasive adenocarcinoma compared to PTEN single KO mice. These changes are 
accompanied by weaker EMT-like characteristics in cancer cells (Zhang et al., 2016d).  
 
 Primary tumors can also become resistant to therapy because of the EMT/inflammation 
alliance. In lung cancer cells, Erlotinib-induced autocrine IL-8 production induces EMT and triggers 
Erlotinib resistance via the p38 MAP-kinase pathway. IL-8 neutralization effectively restores both an 
epithelial phenotype and Erlotinib sensitivity (Fernando et al., 2016). 
 
EMT in association with inflammation has also been connected with higher stages of cancer 
progression in several studies. An important step in metastatic progression of tumors is the 
liberation and survival of circulating tumor cells. In patients with inflammatory breast cancer, a 
correlation exists between immune activation and the presence of circulating tumor cells (CTCs) with 
EMT characteristics (Cohen et al., 2015). Indeed, among 16 tested patients, 6 patients have high 
numbers of circulating TNFα-producing T cells. Among these 6 patients, 4 had EMT-like CTCs. In 
contrast, only one patient with low numbers of TNF-producing T cells (among 10) has EMT-like CTCs 
(Cohen et al., 2015). 
Finally, most clinical data regarding the EMT/inflammation axis have highlighted its correlation with 
metastatic stage and poor outcome. This has been proven to be relevant in multiple cancer entities. 
In colorectal cancer specimens, concomitant expression of IL-8 and CCL20 correlates with E-cadherin 
loss and with lymph node and liver metastasis (Cheng et al., 2014). CCL20-IL-8 double positivity is 
also linked to a shorter overall survival (OS) and disease-free survival (DFS) in these patients. Still in 
colorectal cancer, the expression of IL-6 and STAT3 and the absence of miR-34 (altogether 
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of 425 patients (Rokavec et al., 2014) In breast cancer, the expression of Shohl2 – a transcription 
factor of the bHLH family which inhibits EMT by repressing IL-8 expression in vitro (Ji et al., 2016) – is 
reduced in metastases compared to primary tumors. In mouse xenografts, ectopic expression of 
Shohl2 inhibits metastasis outgrowth, while Shohl2 knockdown boosts metastasis formation. Finally, 
Shohl2 and IL-8 protein expression are negatively correlated in a cohort of 12 breast cancer samples 
(Ji et al., 2016). The CCL18/GM-CSF/EMT loop described above links EMT to macrophages in a pro-
metastatic pathway. CCL18 and GM-CSF expression are correlated (i) to each other and (ii) to EMT-
like features in human breast cancer specimens, and GM-CSF expression predicts a shorter DFS (Su 
et al., 2014). 
 
In ovarian carcinoma, CCL5 is produced by ovarian cancer stem-like cells, where it induces EMT in 
non-cancer stem-like cells. CCL5 and CCR5 expression are also associated with ovarian cancer 
metastasis (Long et al., 2015). CCL18, which induces EMT in ovarian cancer cells in vitro,  is also 
associated with high tumor grade and metastasis in ovarian cancer patients (Wang et al., 2016). High 
EMT/hypoxia-associated CCL20 expression has been associated with poor patient DFS and OS in a 
cohort of 90 hepatocellular carcinomas (Ye et al., 2016). In two independent cohorts of gastric 
cancer patients – in which TAM density is associated with the expression of EMT features in cancer 
cells – both TAM density and EMT features are related to a shorter cumulative survival (Yan et al., 
2016; Zhang et al., 2016b). 
 
 In addition, mouse models have been extensively used to further dissect the 
EMT/inflammation/metastasis axis. Using a murine model of breast cancer, De Cock and 
collaborators have elegantly illustrated the functional synergy between inflammation and cancer in 
the promotion of metastatic outgrowth (De Cock et al., 2016). They have generated a dormant cell 
line that is tumorigenic after orthotopic injection, disseminates in the lung but fails to grow there. 
These cells express low levels of EMT-TFs Snail1, Twist1 and ZEB1. Interestingly, doxycycline-
inducible Snail1 or ZEB1 ectopic expression increases metastatic outgrowth. Most importantly, lung 
inflammation, induced by treating the mice with LPS, also leads to a dramatic increase in metastases 
formation, which can be effectively abrogated by ZEB1 knockdown. This phenomenon occurs in 
NOD-SCID mice and is therefore independent of any adaptive immune response, but intriguingly, 
LPS-induced metastatic outgrowth is inhibited by neutrophil depletion. So this indicates that EMT 
and inflammation are mechanistically required to permit metastasis in this model. In a xenograft 
model of lung adenocarcinoma, injection of cancer cells that stably overexpress IL-6 leads to the 
formation of tumors with EMT characteristics (E-cadherin loss and vimentin expression) and in an 
increased number of lung metastases (Zhao et al., 2014). In another study, IL-17-induced EMT results 
in increased metastatic numbers in nude mice, in the above-mentioned gastric cancer xenograft 
model (Jiang et al., 2017). In murine melanoma RETAAD mice presented above, depletion of MDSCs 
leads to a decrease in EMT marker expression, impairment of tumor growth and decreased cancer 
cell dissemination (Toh et al., 2011). In melanoma xenograft models, Snail1 transfectants (or cells 
expressing Snail1 following TGFβ treatment) acquire EMT features and this results in a shorter 
overall survival of mice (Kudo-Saito et al., 2009). This aggressiveness relies on local 
immunosuppression, as characterized by TSP1 expression, impairment of dendritic cells and 
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Finally, mast cells promote metastasis of bladder cancer in mice, in an EMT-dependent fashion. It 
has been shown that when mast cells are co-cultured with bladder cancer cells, CCL2 expression is 
elevated (after ERβ decrease) and EMT is activated in cancer cells, which express MMP-9 and display 
enhanced invasive properties. In mouse xenograft, co-implantation of mast cells with tumor cells 
increases metastatic burden. This metastatic advantage is reversed by an ERbet antagonist. So 
globally, mast cells promote metastasis of bladder cancer in mice in a CCL2/CCR2/EMT/MMP9-
dependent mechanism (Rao et al., 2016). 
 
5. Concluding remarks 
Studying EMT and inflammation has been difficult because both phenomena are highly 
regulated in time and space. All data collected from immunohistochemistry in human specimens are 
therefore only snapshots that provide associative data. Furthermore, most available models to study 
EMT in time-lines are either cell-based models (migration, invasiveness in vitro) that fail to 
reconstitute the complexity in the living environment, or mouse models, in which the study of 
inflammation, or at least its translation into human data, is complicated by the discrepancies in 
inflammatory markers between both species.  
 
There is clearly, however, a multifaceted, sustained crosstalk between cancer cells 
undergoing EMT-like changes and the cellular actors of inflammation. Tumors are generally 
described as a wound that never heals, generating a chronic, unresolved inflammatory reaction, 
which is fueled by a local cytokine storm. EMT programs most certainly play a central role in 
establishing and maintaining this local cytokine storm. Reciprocally, inflammatory cells present at 
the tumor site keep producing EMT-inducing factors. Supportively, tumor cells displaying EMT-like 
features are most often encountered at the periphery of tumor islets, at the tumor-stroma interface. 
 
The EMT-inflammation axis definitely fosters aggressiveness of the primary tumors as 
illustrated in a number of mouse models, and markers of EMT and inflammation are correlated with 
poor outcome in patient cohorts of multiple cancers. To this day several anti-inflammatory agents 
have been developed and tested for cancer treatment (Crusz and Balkwill, 2015). Conversely, 
despite a likely implication of EMT in specific steps of the metastatic progression, EMT-positive 
tumor cells have not been successfully tackled yet. In this context, we believe that a better 
understanding of the mechanisms behind the EMT/inflammation alliance might open new 
perspectives on anti-inflammatory therapeutic strategies. 
Figure legends 
Figure 1: Schematic representation of the soluble factor-mediated interactions between cancer cells 
undergoing EMT-like changes and innate immune cells. RTK= receptor tyrosine kinase; GPCR= G 
protein-coupled receptor; TAM: tumor-associated macrophages; MDSCs: myeloid-derived 
suppressor cells; Th1/Tc: T helper one cell / cytotoxic T cell. The pink Pacman-shaped symbol 
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Figure 2: Overview of major signaling cascades leading to EMT program activation and inflammatory 
target gene activation in cancer cells.  
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Cellular origin Evidence of EMT pathway activation in cancer 
cells 




- Increased invasive properties 
- E-cadherin drop 
-  N-cadherin and Vimentin expression 
Hepatocellular 
carcinoma  
(Zhu et al., 
2016) 
- Slug and ZEB1 expression 
- Increased cell migration 
- E-cadherin drop 
Renal cell 
carcinoma  
(Sun et al., 
2016) 
- Increased invasion and migration 
- E-cadherin drop 
- Vimentin and N-cadherin expression 
Papillary 
thyroid cancer  
(Lv et al., 
2015) 
- Altered mRNA expression of Snail1, ZEB1, E-
cadherin, fibronectin, vimentin, TGM2 
Breast cancer  (Cohen et 
al., 2015; 
Elghonaimy 
et al., 2016) 
- E-cadherin drop 
- Vimentin expression 






et al., 2016) 
TGFβ Ubiquitous - Elongated cell shape 
- Low E-to-N-cadherin ratio, vimentin 
expression 
- Smad-dependent signaling 
- Smad-independent signaling 
Breast cancer (Johansson 




et al., 2016) 
- Increased migration and invasion 
- E-cadherin drop 
- N-cadherin expression 
- Snail1, Snail2 and ZEB1 gene expression 
Lung cancer (Wu et al., 
2016b) 
- Morphological hcanges 
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- Vimentin expression 
- Gene and protein expression of EPCAM (and 
stemness markers) 
- Invasion and migration 
IL-1β Macrophages, 
tumor cells 
- ZEB1 expression 
- E-cadherin drop 
- Morphological changes 
- Increased invasiveness 
Colorectal 
cancer  
(Li et al., 
2012b) 
- Snail1 and Slug expression 
- Vimentin  
- E-cadherin drop 










IL-6 T cells, 
macrophages, 
tumor cells 
- Morphological changes 
- JAK2/STAT3/Snail1 pathway activation 
- E-cadherin drop 
- Vimentin expression 
- Increased migration 




- JAK2/STAT3/Twist1 activation 
- E-cadherin drop, 
- Vimentin, N-cadherin and fibronectin 
expression 




- Altered mRNA expression of vimentin, Snail1, 
Slug and ZEB1 





- Multiple markers (E-cadherin, N-cadherin, 
Twist, vimentin, MMP9, VEGF, TGFβ) 
- Increased migratory properties 
NSCLC  (Lee et al., 
2016) 
IL-8 T cells, 
macrophages, 
tumor cells 
- ZEB1, Snail1 and Slug activation 





- JAK2/STAT3/Snail1 activation 
- E-cadherin drop 
- N-cadherin expression 
- Increased migratory properties 
Hepatocellular 
carcinoma 
(Fu et al., 
2015) 




- Morphological chances 
- Increased migratory and invasive properties  
- E-cadherin drop 
- N-cadherin, vimentin, fibronectin expression 
Breast cancer  (Ji et al., 
2016) 
- E-cadherin drop 
- Vimentin and  Fibronectin expression 
- Increased invasive properties 
NSCLC  (Fernando 
et al., 2016) 
- E-cadherin drop 
- Increased migratory properties 





- Only studied in combination with IL-6 
- Twist expression 
- Increased migration 
- E-cadherin drop 
- Vimentin and fibronectin expression 
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- E-cadherin drop, increased Snail1 expression 
- STAT3 activation 
- MMP9 expression 
- Increased migration  
Prostate cancer (Izumi et al., 
2013) 
- Increased invasion and migration 
- E-cadherin/Vimentin switch, increased N-
cadherin 
- Increased Snail1 and Twist gene expression 
- Increased MMP9 expression 
Bladder cancer (Rao et al., 
2016) 






- E-cadherin drop 
- Expression of vimentin, Snail1, Slug 
- Increased invasive properties 
Ovarian cancer  (Long et al., 
2015) 
- E-cadherin drop 





- Migratory and invasive properties only Triple-negative 
breast cancer  
(D'Esposito 
et al., 2016) 
CCL18 Macrophages, 
tumor cells 
- Migratory and invasive properties only Ovarian cancer  (Wang et 
al., 2016) 
- E-cadherin drop, 
- Viment expression 
- Migratory and invasive properties 
Breast cancer (Su et al., 
2014) 
- Increased invasive properties 







Lymphocytes - Morphological changes 
- E-cadherin drop 
- Vimentin expression 





Kapur et al., 
2016) 
CCL21 Lymphocytes - ERK1/2/NF-κB signaling 
- Increased invasive properties 
- E-cadherin drop 







- Wnt/β-catenin pathway activation, GSK3β 
stabilization 
- Snail1 and Slug gene expression 
- E-cadherin/Vimentin switch 
Esophageal 
cancer  




- Snail1 and Slug expression 
- E-cadherin/Vimentin switch 
Prostate cancer (Zhang et 
al., 2016d) 
- E-cadherin/vimentin switch 
- Increased invasive properties 
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